It’s been four years since the Defend Trade Secrets Act of 2016 (DTSA) created a new pathway for parties to sue in federal court for trade secret misappropriation. Over that time, several new developments have arisen under the DTSA, including important case law dealing with the scope of trade secret protection, jurisdiction, damages, and other remedies. Join experienced intellectual property litigator Christopher Loh as he covers these new developments, provides best practices and potential pitfalls when litigating under the DTSA, and teaches lessons based on the past four years of DTSA law on how employers can protect themselves from trade secret misappropriation.
Christopher Loh practices complex patent litigation in the areas of pharmaceuticals, biotechnology and chemistry. Over the past fifteen years, he has litigated patent cases involving anti-HIV therapies, anti-hepatitis drugs, antidepressants and statins, including as lead counsel. He has experience arguing before the United States Court of Appeals for the Federal Circuit, and has won on behalf of patent owners in inter partes review proceedings before the Patent Trial and Appeal Board. In addition to his litigation work, Christopher also counsels clients on transactional and patent prosecution issues concerning both small-molecule drugs and biological products such as recombinant antibodies, and advises clients on a range of intellectual property matters including inventorship, trade secrets, and licensing.
Christopher is a frequent author and commentator on intellectual property issues, and has twice won the Burton Award for Legal Achievement in recognition of his exceptional writing. His publications have appeared in Lexology, the National Law Journal, the New York Law Journal, Bloomberg IP and Managing Intellectual Property.
In law school, Christopher served as Notes Editor for the Columbia Business Law Review and also interned at the New York Volunteer Lawyers for the Arts, counseling clients on copyright, trademark and artist rights issues.